[In vivo dissolving of gall-stones: the effect of chenodeoxycholic acid. (author's transl)]
- PMID: 170051
- DOI: 10.1055/s-0028-1106432
[In vivo dissolving of gall-stones: the effect of chenodeoxycholic acid. (author's transl)]
Abstract
Chenodeoxycholic acid (CDCA) was administered for an average of 15 months to 14 patients with gall-stones. The gall-stones were radiolucent in all but one instance (solitary calcified stone). Stones dissolved completely after 12 and 15 months of therapy, respectively, in two patients, while in four the size of the stones diminished. No change occurred in the remaining patients. In five patients multiple stones dissolved, while in one a radiolucent solitary stone dissolved. In one patient, with a negative cholecystogram for a time before being treated with CDCA, the gall-bladder perforated while on treatment. CDCA was well tolerated by all patients: upper abdominal discomfort disappeared during CDCA treatment in two patients and improved in nine. Only side-effect was occasional mild diarrhoea in five patients. Bile was analysed in seven patients, supersaturation with cholesterol being found in five. Biliary lipid composition became normal during CDCA treatment in these five patients. Serum triglyceride levels fell during CDCA administration in ten of eleven patients in which serum measurements were made; the greatest fall occurred in the five patients with hypertriglyceridaemia. The fall in triglyceride levels was associated with a diminution of the pre-beta-lipo-protein fraction and the chylomicron fraction. No significant change occurred in serum cholesterol levels.
Similar articles
-
Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones.Br Med J. 1978 Jun 10;1(6126):1509-12. doi: 10.1136/bmj.1.6126.1509. Br Med J. 1978. PMID: 656777 Free PMC article.
-
The effect of chenodeoxycholic acid (CDCA) on cholesterol absorption.Gastroenterology. 1979 Aug;77(2):223-30. Gastroenterology. 1979. PMID: 447035
-
Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients with radiolucent gallstones. Factors influencing efficacy, withdrawal, symptoms and side effects and post-dissolution recurrence.Medicine (Baltimore). 1982 Mar;61(2):86-97. doi: 10.1097/00005792-198203000-00003. Medicine (Baltimore). 1982. PMID: 7062856
-
Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.Drugs. 1981 Feb;21(2):90-119. doi: 10.2165/00003495-198121020-00002. Drugs. 1981. PMID: 7009140 Review.
-
[Current status of treatment of gall stones with chenodeoxycholic acid].Tijdschr Gastroenterol. 1975;18(1):49-63. Tijdschr Gastroenterol. 1975. PMID: 808879 Review. Dutch. No abstract available.
Cited by
-
Gallstone dissolution with chenodeoxycholic acid. A clinical study.Klin Wochenschr. 1980 Mar 17;58(6):313-20. doi: 10.1007/BF01476574. Klin Wochenschr. 1980. PMID: 7374101
-
Role of bile acids in the regulation of the metabolic pathways.World J Diabetes. 2016 Jul 10;7(13):260-70. doi: 10.4239/wjd.v7.i13.260. World J Diabetes. 2016. PMID: 27433295 Free PMC article. Review.
-
Does chenodesoxycholic acid have a lipid lowering effect in primary hyperlipoproteinemia?Eur J Clin Pharmacol. 1976 Jun 15;10(2):147-9. doi: 10.1007/BF00609474. Eur J Clin Pharmacol. 1976. PMID: 964291 No abstract available.
-
Relationship between serum and biliary bile acids as an indicator of chenodeoxycholic and ursodeoxycholic acid-induced hepatotoxicity in the rhesus monkey.Dig Dis Sci. 1982 May;27(5):417-24. doi: 10.1007/BF01295650. Dig Dis Sci. 1982. PMID: 7075428
-
Endocrine and paracrine role of bile acids.World J Gastroenterol. 2008 Oct 7;14(37):5620-9. doi: 10.3748/wjg.14.5620. World J Gastroenterol. 2008. PMID: 18837077 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources